I. Kawabata

Phase 1 dose-escalation study of S-222611, an oral reversible dual tyrosine kinase inhibitor of EGFR and HER2, in patients with solid tumours.

R. Plummer, E. Frenkel, S. Matsumoto, 2015, European journal of cancer.

An extended phase Ib study of epertinib, an orally active reversible dual EGFR/HER2 tyrosine kinase inhibitor, in patients with solid tumours.

R. Plummer, M. Toulmonde, A. Italiano, 2018, European journal of cancer.

Abstract P4-12-24: Phase I trial of S-222611, a dual tyrosine kinase inhibitor of EGFR and HER2, with preliminary evidence of efficacy in patients (pts) with heavily-pretreated HER2-positive metastatic breast cancer

R. Plummer, J. Spicer, D. Jodrell, 2013 .

A phase I study of S-222611 an oral reversible dual inhibitor of EGFR and HER2, in patients with solid tumors.

R. Plummer, E. Frenkel, M. Jamal-Hanjani, 2012 .